In this edition:
Sacituzumab govitecan for hormone receptor-positive advanced breast cancer
Trastuzumab deruxtecan for HER2-positive metastatic breast cancer
Patritumab deruxtecan for HER3-expressing metastatic breast cancer
CDK 4/6 inhibitor after progression on CDK 4/6 inhibitor
OS with palbociclib in ER+/HER2- advanced breast cancer
Fulvestrant + capivasertib in ER+ breast cancer (FAKTION): OS update
Systemic therapy +/- SBRT for oligometastatic breast cancer
Trastuzumab deruxtecan for HER2-low unresectable and/or metastatic breast cancer
Long-term outcomes of adjuvant denosumab in breast cancer
Ribociclib in hormone receptor-positive/ HER2- advanced breast cancer
Please login below to download this issue (PDF)